Spero Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SPRO Nasdaq 2836 sperotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 2nd, 2026 2:05 pm
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 3rd, 2026 2:05 pm
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Sep 2nd, 2026 2:01 pm
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript - Aug 19th, 2026 3:28 pm
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 13th, 2026 6:30 am
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... - Aug 12th, 2026 11:01 pm
Spero Therapeutics Q2 Earnings Call Highlights - Aug 12th, 2026 8:04 pm
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update - Aug 12th, 2026 2:01 pm
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Aug 4th, 2026 2:01 pm
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - Jul 27th, 2026 6:00 am
Innovent licenses IBI355 rights to Spero for up to $1.1bn - Jul 15th, 2026 4:01 am
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals - Jul 15th, 2026 3:18 am
Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) - Jul 14th, 2026 4:46 am
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties - Jul 14th, 2026 4:02 am
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody - Jul 14th, 2026 4:00 am
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody - Jul 14th, 2026 4:00 am
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - Jul 8th, 2026 12:00 am
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - Jun 29th, 2026 5:30 am